Atopic Dermatitis
Conditions
Keywords
Teledermatology, Telemedicine, Atopic Dermatitis
Brief summary
The purpose of this study is to determine if an asynchronous online model of teledermatology can achieve similar clinical outcomes as compared to conventional in-office care for the management of atopic dermatitis. The investigators also aim to determine the effects of this online care model on patient quality of life as well as patient and physician satisfaction. The investigators' hypotheses include the following: 1. Compared to in-person visits, the online care model will result in similar clinical improvement in atopic dermatitis disease severity. 2. Compared to in-person visits, the online care model will result in similar improvements in quality of life. 3. Providers and subjects in the online group will achieve a similar level of overall satisfaction as those in the in-person group.
Interventions
Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
Sponsors
University of California, Davis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 4 years or older at time of consent, may be male or female. * Meet the Hanifin diagnostic criteria for atopic dermatitis. * Capable of giving informed consent (for patients less than 18 years of age, assent will be obtained from the minor and informed consent will be obtained from a legal guardian). * Able to image their skin or have someone do it for them. * Able to adhere to the study visit schedule and other protocol requirements. * Have access to a computer with internet connection, a digital camera, and an e-mail address.
Exclusion criteria
* Non English speaking patients. * Patients requiring systemic treatment (e.g., cyclosporine, phototherapy). * Patients requiring close laboratory monitoring.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eczema Area and Severity Index (EASI) | Every 8 weeks |
| Patient-oriented Eczema Measure (POEM) | Every 8 weeks |
Countries
United States
Outcome results
None listed